Dr. Ami Shah is a Professor of Medicine and Director of the Division of Rheumatology at the Johns Hopkins University School of Medicine. Dr. Shah also serves as the Co-Director of the Johns Hopkins Scleroderma Center.  

Dr. Shah is a graduate of the Massachusetts Institute of Technology and Johns Hopkins University School of Medicine. She completed her internal medicine residency training at Stanford University Hospital & Clinics and rheumatology post-doctoral fellowship at Johns Hopkins. She subsequently completed a Master of Health Science in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.  

Dr. Shah’s clinical practice is focused on the broad spectrum of patients with scleroderma, Raynaud's phenomenon and related fibrosing disorders. Her clinical research program has focused on the interface between cancer and autoimmunity in scleroderma, myositis and the newly emerging area of rheumatic immune related adverse events due to immune checkpoint inhibitor therapy.  Dr. Shah also has an active research program in other clinical and therapeutic aspects of scleroderma, including early detection of cardiopulmonary complications and improving outcome measures and therapeutics for Raynaud's phenomenon.  

Dr. Shah serves on the Scientific Advisory Council of the Rheumatology Research Foundation and on the Steering Committee of the US CONQUER (Collaborative National Quality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis) Registry. She is a founding Co-PI of the US RADIOS (Rheumatology Adverse Events due to Immunotherapy Observational Study) Consortium. In 2018, Dr. Shah's research contributions were recognized at the 5th Systemic Sclerosis World Congress with receipt of the Edith Busch Prize for Young Investigators. In 2020, she was honored to receive the Henry Kunkel Young Investigator Award from the American College of Rheumatology.